LIV001

Phase 1Small molecule

LLiveome Inc.

LIV001 is one of 44 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ulcerative ColitisNot yet recruiting

Ulcerative ColitisPhase 1

Not yet recruiting

Competition

Competitive Landscape

91 competitors in Ulcerative Colitis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Phase 3

10 2

Jyseleca

Gilead

Phase 3

6 3

Skyrizi

AbbVie

Phase 3

6 4

Humira

RRanbaxy Laboratories Limited

Phase 3

19 5

Velsipity

Pfizer

Phase 3

10 6

Mesalazine

Ferring

Phase 3

17 7

Plaquenil

Jazz Pharmaceuticals

Phase 2

1 8

Zasocitinib

Takeda

Phase 2

1 9

Lutikizumab

AbbVie

Phase 2

1 10

ABX464

AAbivax S.A.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Ulcerative Colitis2 trials

A Study of LIV001 in Healthy Subjects and Those with Mild-to-Moderate Active Ulcerative Colitis (UC)

Completed·LLiveome Inc.·Phase 1·NCT05975047·38 enrolled

LIV001 in Patients with Mild-to-Moderate Active Ulcerative Colitis (UC)

Not yet recruiting·LLiveome Inc.·Phase 1·NCT06749795·15 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for LIV001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LIV001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LIV001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liveome Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLiveome Inc.

LIV001

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Ulcerative Colitis2 trials

References

Drug Info

Quick Facts

Related News